Bioton (BIO.WA) Stock Price
Bioton Price
Over the last 19 years Bioton grew revenue by 1.4% annually, reaching 282.52 M PLN. Earnings per share have declined at 21.4% per year over the last 19 years. For Bioton, the net margin of 1.2% is broadly stable versus 1.8% a few years ago. The stock trades about 2% above its 52-week low.
Bioton stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Bioton over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bioton stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bioton's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Bioton Price |
|---|---|
| 9/4/2026 | 3.80 PLN |
| 9/3/2026 | 3.77 PLN |
| 9/2/2026 | 3.79 PLN |
| 9/1/2026 | 3.74 PLN |
| 8/31/2026 | 3.78 PLN |
| 8/28/2026 | 3.79 PLN |
| 8/27/2026 | 3.81 PLN |
| 8/26/2026 | 3.78 PLN |
| 8/25/2026 | 3.76 PLN |
| 8/24/2026 | 3.77 PLN |
| 8/21/2026 | 3.77 PLN |
| 8/20/2026 | 3.82 PLN |
| 8/19/2026 | 3.77 PLN |
| 8/18/2026 | 3.80 PLN |
| 8/17/2026 | 3.81 PLN |
| 8/14/2026 | 3.82 PLN |
| 8/13/2026 | 3.84 PLN |
| 8/12/2026 | 3.93 PLN |
| 8/11/2026 | 3.90 PLN |
| 8/10/2026 | 3.89 PLN |
| 8/7/2026 | 3.85 PLN |
| 8/6/2026 | 3.83 PLN |
| 8/5/2026 | 3.85 PLN |
| 8/4/2026 | 3.84 PLN |
| 7/31/2026 | 3.81 PLN |
| 7/30/2026 | 3.86 PLN |
| 7/29/2026 | 3.87 PLN |
| 7/28/2026 | 3.80 PLN |
| 7/27/2026 | 3.82 PLN |
| 7/24/2026 | 3.85 PLN |
Bioton Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioton Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM PLN |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM PLN |
| EBITM PLN |
| EBIT MARGIN% |
| NET INCOMEM PLN |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 406.00 | 340.00 | 377.00 | 332.00 | 277.00 | 361.00 | 241.00 | 202.00 | 221.00 | 163.00 | 233.00 | 181.00 | 207.00 | 282.00 | 266.00 | 285.00 |
| 40.48 | -16.26 | 10.88 | -11.94 | -16.57 | 30.32 | -33.24 | -16.18 | 9.41 | -26.24 | 42.94 | -22.32 | 14.36 | 36.23 | -5.67 | 7.14 |
| 52.46 | 42.65 | 41.91 | 48.19 | 49.82 | 51.52 | 48.13 | 50.50 | 47.06 | 47.85 | 40.77 | 39.78 | 30.92 | 32.27 | 32.27 | 32.27 |
| 213.00 | 145.00 | 158.00 | 160.00 | 138.00 | 186.00 | 116.00 | 102.00 | 104.00 | 78.00 | 95.00 | 72.00 | 64.00 | 91.00 | 85.84 | 91.97 |
| 66.00 | 8.00 | 21.00 | 11.00 | -10.00 | 2.00 | -50.00 | -71.00 | 30.00 | 15.00 | 27.00 | 13.00 | -4.00 | 13.00 | 22.00 | 35.00 |
| 16.26 | 2.35 | 5.57 | 3.31 | -3.61 | 0.55 | -20.75 | -35.15 | 13.57 | 9.20 | 11.59 | 7.18 | -1.93 | 4.61 | 8.27 | 12.28 |
| 37.00 | -6.00 | 3.00 | -522.00 | -28.00 | -20.00 | 26.00 | -126.00 | 33.00 | 2.00 | 1.00 | 2.00 | -15.00 | 3.00 | 12.00 | 22.00 |
| -147.44 | -116.22 | -150.00 | -17,500.00 | -94.64 | -28.57 | -230.00 | -584.62 | -126.19 | -93.94 | -50.00 | 100.00 | -850.00 | -120.00 | 300.00 | 83.33 |
| 71.50 | 84.50 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 | 85.86 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Bioton generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bioton retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bioton's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Bioton has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bioton's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Bioton stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioton Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioton business model & stock analysis
Bioton SWOT Analysis
Strengths
Bioton SA has a strong market presence and brand recognition in the pharmaceutical industry. The company's extensive experience and expertise in the development and manufacturing of biotechnology and pharmaceutical products give it a competitive advantage. Additionally, Bioton SA has a diverse product portfolio, catering to various medical needs.
Weaknesses
One weakness of Bioton SA is its dependence on a limited number of key products. This exposes the company to market fluctuations and risks associated with product failures. Bioton SA may also face challenges in terms of intellectual property protection and maintaining a reliable supply chain.
Opportunities
There are several opportunities for Bioton SA to explore. The increasing global demand for biotechnology and pharmaceutical products presents a growth opportunity for the company. Bioton SA could also consider expanding its product offerings or entering new markets to diversify its revenue streams. Collaborations and partnerships with other industry players could further enhance Bioton SA's market position.
Threats
Bioton SA faces threats from intense competition in the pharmaceutical industry. The presence of both established multinational companies and emerging biotech firms can pose challenges to Bioton SA's market share. Additionally, regulatory changes and stringent compliance requirements may impact the company's operations and product development processes. Economic uncertainties and geopolitical factors can also influence Bioton SA's business environment.
Bioton Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Bioton historical P/E ratio, EBIT multiple, and P/S ratio
Bioton annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Bioton shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioton stock splits
Bioton shareholder structure
| % | Name |
|---|---|
31.64964% | |
7.16463% | |
6.00000% | |
5.03353% | |
5.00000% | |
0.25350% |
Bioton Beneficial Ownership Filings (SEC 13D/G)
Bioton Executives and Management Board
11 members · avg. age 52 · 9 % women
Mr. Jeremy Launders
Chairman of the Management Board, Chief Executive Officer
1.82 M PLN
Management
Mr. Dariusz Trzeciak
Vice President of the Supervisory Board · since 2013
Board of Directors
Mr. Nicola Cadei
Chairman of the Supervisory Board · since 2019
Mr. Ramesh Rajentheran
Vice Chairman of the Supervisory Board · since 2019
Dr. Jubo Liu
Member of the Supervisory Board · since 2016
Mr. Vaidyanathan Viswanath
Member of the Supervisory Board · since 2016
Mr. Tomasz Siembida
Member of the Supervisory Board · since 2017
Mr. Khee Wee Hau
Member of the Supervisory Board
Frequently asked questions about Bioton
The business model of Bioton SA revolves around the development, manufacturing, and distribution of innovative biopharmaceutical products. Bioton SA specializes in the production of recombinant human insulin and insulin analogs, addressing the needs of diabetic patients worldwide. The company focuses on research and development activities to continuously improve their products and expand their portfolio. Bioton SA strives to provide high-quality and affordable healthcare solutions, catering to the growing demand for diabetes treatment options. With their strong commitment to innovation and patient care, Bioton SA aims to establish itself as a leading player in the biopharmaceutical industry.
Bioton SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Bioton SA in the market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, and Merck & Co., Inc.
Bioton SA is a renowned pharmaceutical company with a rich history and background. Established in 1989, Bioton SA has become a pioneer in the field of biotechnology and specializes in the development, production, and marketing of innovative pharmaceuticals. With its headquarters in Poland, Bioton SA has successfully expanded its operations globally. The company has made significant contributions to the medical industry through its cutting-edge research and development efforts, particularly in the fields of diabetes and human insulin production. Bioton SA continuously strives to provide high-quality products and improve global healthcare standards, solidifying its position as a leading player in the pharmaceutical sector.
Bioton SA, a leading pharmaceutical company, has achieved remarkable milestones throughout its existence. The company garnered global recognition for its groundbreaking advancements in the field of biotechnology. Bioton SA successfully introduced innovative pharmaceutical products, including insulin and other life-saving medications, revolutionizing the treatment of diabetes and various other medical conditions. Moreover, the company's dedicated research and development efforts have enabled Bioton SA to expand its product portfolio and consistently deliver high-quality therapeutic solutions to meet the growing healthcare needs of patients worldwide. Bioton SA's commitment to excellence and continuous innovation has established it as a prominent leader in the pharmaceutical industry.
Bioton SA is primarily present in Poland, where it is headquartered. Additionally, Bioton SA has a significant presence in the European market, specifically in countries such as Germany, France, and the United Kingdom.
Bioton SA is a leading biotechnology company that represents a strong set of values and corporate philosophy. The company values innovation, research, and development to provide cutting-edge solutions in the field of biotechnology. Bioton SA focuses on providing high-quality healthcare products and services to improve people's lives. With a commitment to excellence and a customer-centric approach, Bioton SA aims to deliver value to its stakeholders. The company's philosophy centers around sustainable growth, ethical practices, and fostering partnerships to drive success. Bioton SA's dedication to scientific advancement and ethical business conduct makes it a trusted name in the biotechnology industry.
Converted at the current exchange rate, the Bioton share trades at 0.88 EUR (3.80 PLN).
The Bioton share (BIO.WA) is listed on 4 stock exchanges, including: Frankfurt (7U5.F), London (0DTR.L).
Bioton SA is a Polish biotechnology company that specializes in the development and production of biotechnological and medical products. The company's business model is focused on advancing innovation and research in biotechnology and producing high-quality products suitable for both the Polish and international markets. The company is divided into three divisions: medicine, agriculture, and industry, each offering its own products and services. In medicine, Bioton SA offers a wide range of products for prevention, diagnosis, and therapy of various diseases, including diagnostic kits, vaccines, and therapeutics. In the agriculture division, the company aims to improve global food production through the development and production of animal feed and biotechnological enzymes, which enhance the nutrition of livestock and increase the nutritional value of meat, milk, and eggs. In the industry division, Bioton SA develops biotechnological enzymes and processes used in the food and beverage industry, as well as other industries such as textiles and paper, to improve production efficiency and product quality. The company emphasizes its strong presence in research and development, with a team of highly qualified scientists and technicians dedicated to researching and developing new products. Bioton SA also invests heavily in collaboration with universities and research institutes to stay at the forefront of technology and drive continuous innovation. Additionally, the company highlights its strong presence in the international market, with branches in several countries in Europe, Asia, and South America. It also operates several subsidiaries specialized in selling and marketing products in specific markets. Overall, Bioton SA's business model is focused on producing high-quality products while promoting the growth and development of the biotechnology industry. The company emphasizes its presence in various industries and markets and its ability to conduct innovation and research at the highest level.
The expected revenue of Bioton is 266.00 M PLN. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Bioton is 12.02 M PLN. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bioton is currently 27.14. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bioton stock.
The price-to-sales ratio (P/S) of Bioton is currently 1.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bioton stock.
The Eulerpool Quality Score for Bioton is 2/10.
The ISIN of Bioton is PLBIOTN00029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bioton is A0D9SD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bioton is BIO.WA. The ticker symbol is used to trade Bioton shares on the stock exchange.
Bioton paid dividends every year for the past 0 years.
Bioton is assigned to the 'Health' sector.
The dividends of Bioton are distributed in PLN.
Bioton stock
Bioton Peer Group
Bioton Ticker
Bioton FIGI
All fundamentals and in-depth analysis of Bioton
Our stock analysis for Bioton stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioton. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.